Stalicla
Genève
About Stalicla
Stalicla is a clinical stage, precision molecular neuroscience biotech company with a mature pipeline for patients with Neurodevelopmental Disorders (NDDs) and Neuropsychiatric disorders. Stalicla’s unique approach addresses a principal weakness in the drug development process for NDD’s and neuropsychiatric disorders: behavior is a terrible biomarker. Clinical psychiatric and neurodevelopmental diagnoses encompass a broad diversity of underlying biology. This has contributed to drug development failure by diluting true responders in a population of patients with heterogeneous biology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $56.0M
- Last round: Corporate Round (Jun 2025)
- Website: stalicla.com
- Phone: +41 22-545-12-42
Industries & Categories
Biopharma, Biotechnology, Life Science, Medical, Neuroscience
Social Profiles
Canonical: https://fsome.com/organization/stalicla-86374 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.